Power Law company profile

Vicebio

Biotech & Life Sciences · London, United Kingdom · Founded 2019 Unicorn

Multi-pathogen respiratory vaccines using Molecular Clamp technology

Valuation

$1–2.5B

Latest valuation · 2026

Unlock exact value

Headcount

<100

Current team size

Unlock exact value

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

8 investors on Vicebio's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage

Medicxi

Series B+ 7 investors entered at this stage

TCGX

Avoro Capital Advisors

venBio Partners

UniQuest Extension Fund

Goldman Sachs Asset Management

UniQuest

The University of Queensland

Global footprint

Where Vicebio has talent and traffic

Workforce by country

4 countries with
team presence

🇧🇪 Belgium54.8%

🇦🇺 Australia26.4%

🇺🇸 United States12.2%

🇬🇧 United Kingdom6.6%

4 countries shown

Web traffic by country

1.7K monthly visits
across markets

🇺🇸 United States82.4%

🇩🇪 Germany17.6%

🇹🇷 Turkey0%

🇯🇵 Japan0%

🇲🇽 Mexico0%

Top 5 markets shown

Market sentiment

What the market is saying about Vicebio

An AI-synthesized read of the highest-engagement posts about Vicebio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Vicebio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles